Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil by Toledo, Rodrigo A. et al.
  Universidade de São Paulo
 
2012
 
Narrowing the gap of personalized medicine in
emerging countries: the case of multiple
endocrine neoplasias in Brazil
 
 
Clinics,v.67,n.,p.3-6,2012
http://www.producao.usp.br/handle/BDPI/40460
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade Scielo
REVIEW
Narrowing the gap of personalized medicine in
emerging countries: the case of multiple endocrine
neoplasias in Brazil
Rodrigo A. Toledo, Tomoko Sekiya, Viviane C. Longuini, Flavia L. Coutinho, Delmar M. Lourenc¸o Jr.,
Sergio P. A. Toledo
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Endocrine Genetics Unit (LIM-25), Endocrinology Division, Sa˜o Paulo,
SP/Brazil.
The finished version of the human genome sequence was completed in 2003, and this event initiated a revolution in
medical practice, which is usually referred to as the age of genomic or personalized medicine. Genomic medicine
aims to be predictive, personalized, preventive, and also participative (4Ps). It offers a new approach to several
pathological conditions, although its impact so far has been more evident in mendelian diseases. This article briefly
reviews the potential advantages of this approach, and also some issues that may arise in the attempt to apply the
accumulated knowledge from genomic medicine to clinical practice in emerging countries. The advantages of
applying genomic medicine into clinical practice are obvious, enabling prediction, prevention, and early diagnosis
and treatment of several genetic disorders. However, there are also some issues, such as those related to: (a) the
need for approval of a law equivalent to the Genetic Information Nondiscrimination Act, which was approved in
2008 in the USA; (b) the need for private and public funding for genetics and genomics; (c) the need for
development of innovative healthcare systems that may substantially cut costs (e.g. costs of periodic medical follow-
up); (d) the need for new graduate and postgraduate curricula in which genomic medicine is emphasized; and (e)
the need to adequately inform the population and possible consumers of genetic testing, with reference to the
basic aspects of genomic medicine.
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INTRODUCTION
The finished version of the human genome sequence was
completed in 2003, and this event initiated a revolution in
medical practice, which is usually referred to as the age of
genomic medicine or personalized medicine (1,2). Genomic
medicine aims to be predictive, personalized, and preven-
tive, mostly with regard to mendelian inherited disease
forms, but also to complex disorders (3). Further, it must be
participative, because patients, their at-risk relatives, and
the potential consumers of genetic testing should be aware
of the pros and cons of this new technology. Thus, genomic
medicine is the art and science of the four Ps (4Ps) (4). The
effect of genomic medicine on clinical diagnosis and
treatment is currently limited; however, it is almost certain
that its impact will increase exponentially in the coming
years, as costs of genome sequencing are decreasing rapidly
and may achieve the expected US$1,000 in the near future. It
is anticipated that genomic medicine may help to improve
the quality of life and prolong human survival. However,
the genetic analyses that have been developed and which
have been ready to use for some time now, have been
underutilized in the past decade (3). Although the fields of
genetics and genomics are well established in developed
countries, important progress has been made in other
countries in recent years, especially in the emerging
countries (5). In order to the increase this development
and growth, these countries should immediately begin to
tackle essential issues, some of which are discussed below
(1–4).
Reimbursement
A crucial issue is the reimbursement of genetic testing by
the health insurance companies. Although the costs of
genetic testing are reducing, it remains expensive for most
of the population. In addition, an adult positive-mutation
carrier may have several at-risk children to be tested.
However, extensive data evaluating the economics of
genetic testing are lacking (http://www.genome.gov/
19016729). Hopefully, in the near future, health insurance
companies that are established in emerging countries may
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agree to cover the costs of genetic diagnostic testing of their
clients, and thus offer this new technology to patients and
their at-risk relatives.
Confidentiality
An important issue is the confidentially of genetic test
results. In 2008, the Genetic Information Nondiscrimination
Act (GINA) was approved in the USA. Approval of this law
was strongly supported by Senator Edward Kennedy, among
others (http://help.senate.gov/old_site/Min_press/2008_
04_24_a.pdf). GINA is considered to be one of the most
important antidiscrimination laws approved so far in the
USA. The law has two parts: one that prohibits genetic
discrimination in health insurance, and one that prohibits
genetic discrimination in employment.
In large areas of the world, genetic testing is not properly
regulated. The lack of a GINA-like law in many countries
may limit the interest of many healthy individuals and
patients in participating in genetic testing. Presently, the
approval of such a law constitutes a major challenge to
legislators all over the world. The global approval of
antidiscrimination laws would constitute one of the bases
for a modern and humanized genomic medicine for the 21st
century.
However, genetic testing is a fast-growing field and
present laws do not cover every situation (http://health.
nih.gov/topic/GeneticTestingCounseling). A critical issue
is the routine inclusion of genetic testing results in a
person’s medical records, with the possibility that these data
may be accessed by employers and health insurance
companies. As far as we know, this specific and critical
aspect requires further regulation in many countries. A
valid approach would be to include genetic testing results in
personal records only after obtaining written, specific
informed consent from the patient or his/her legal
guardian.
Public and private funding
Public healthcare systems from different countries should
consider the potential benefits of funding programs,
probably based initially on searching for mendelian germ-
line genetic mutations, such as those occurring in cancer
genetics. Extensive data evaluating the economics of genetic
testing are needed to give further support to these
initiatives. Family screening for mendelian diseases could
be the first choice (3). However, large portions of the
world’s population do not have access to a private
healthcare system and cannot afford the expense involved
in genetic testing.
It is possible that private groups supplying investment
funds may play an important role by supporting small
innovative companies who are researching into new and
informative genetic tests.
New medical curricula
In general, medical schools in many countries have not yet
developed innovative curricula that introduce medical
doctors to the world of genomic medicine. Therefore, there
should be a strong effort, particularly in emerging countries,
to educate graduate and postgraduate medical students in
the rapidly advancing field of medical genetics and genomic
medicine. In this century, clinical practitioners will be
required to have substantial knowledge of personalized
medicine to better manage patients with inherited conditions.
Information to the community
Finally, the public should be informed about the basic
findings and advantages to be gained from the enormous
amount of research data related to genomic medicine. This
information may bring several benefits. First, it would make
it easier for a person to search their family medical history to
find out whether there is an inherited condition in the
family, facilitate the personal clinical and molecular
diagnosis for any affected members, and allow members
to take advantage of genetic screening, early diagnosis, and
preventive treatment.
This also raises new challenges, however. The US Food
and Drug Administration has been investigating how best
to oversee and validate direct-to-consumer test kits. There is
concern that doubts over the validity of these tests, and
inconsistency in results from different companies, may
result in a strict regulatory framework that will hamper
scientific innovation. Nature has examined and reported
these issues (http://dx.doi.org/10.1038/news.2010.382).
Genomic medicine in emerging countries: the
Brazilian experience
Recently, a series of six papers discussing the Brazilian
public health system were published in The Lancet (6–10).
These papers identified important advances in the Brazilian
healthcare system over the past decade, as well as several
future challenges in this field. Brazil is presently the second
largest emerging country within the BRIC (Brazil, Russia,
India, China) countries, with more than 190 million people.
However, a large proportion of the population does not
have private healthcare insurance, and thus depends on the
Brazilian public health system, the Unified Health System
(SUS). As a result of the economic stability and growth of
the last decade, the Brazilian government is presently
funding projects relating to human genetics and genomics.
The first whole-sequence determination of a plant pathogen,
Xyllela fastidiosa, carried out by the Brazilian ONSA
(Organization for Nucleotide Sequencing and Analysis)
Network, funded by the Sa˜o Paulo State Research
Foundation (FAPESP), was a landmark in genomics science
in this country (11). Further investments have been made by
FAPESP and the National Research Agency (CNPq) in
programs such as the Human Cancer Genome, as well as
medical genetics initiatives that are being developed into
potential applications in the SUS.
In Brazil, the possibility of applying genomic medicine to
clinical practice has not yet had a significant impact. Brazil
has achieved substantial economic growth in the last
decade. Nevertheless, the vast majority of the population
has limited access to modern medicine and especially to
genomic medicine, although some initiatives have been
performed.
An example of a pioneering initiative is the screening of
some of the inherited endocrine neoplasia susceptibility
genes (RET, MEN1, p27Kip1, AIP, and TMEM127). This
program was supported by the SUS, through the FFM
(School of Medicine Foundation), and partially by FAPESP.
We conducted this project from 2000 to 2011 in the largest
non-profit academic hospital in Brazil: the Hospital das
Clı´nicas of the University of Sa˜o Paulo School of Medicine.
DNA samples from 871 patients and their at-risk relatives
were studied. Informed consent was obtained from all
individuals or their parents. DNA from patients diagnosed
with multiple endocrine neoplasia type 1 or 2 (MEN1 or
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MEN2), familial isolated pituitary adenoma (FIPA), and
non-syndromic familial pheochromocytoma (F-PHEO) was
genetically sequenced. Out of the 871 individuals, 346
carriers of disease-causing germline mutations and 525 non-
carriers were identified (12–26). The positive mutation
carriers have greatly benefited from the genetic testing for
the five tumor susceptibility genes. Early diagnosis, genetic
counseling, and recommendation of appropriate and poten-
tially preventive/prophylactic surgeries have been offered
to patients. Consequently, high cure rates have been
observed in this group of patients, particularly in RET-
positive mutation carriers who were genetically detected at
an early age (,10 years) (12–15,24). This strategy demon-
strated that public familial screening programs, attempting
to apply current knowledge from genomic medicine to
medical practice, may have a positive impact on the quality
of healthcare systems in emerging countries.
The feedback of the referral physicians was positive and
demonstrated an evident improvement in their capacity to
manage the genetically diagnosed individuals and their at-risk
relatives. These results confirm that Brazil needs new medical
curricula emphasizing recent advances in the study of the
human genomics, proteomics, and many other ‘‘-omics’’.
In 2009, the integration of genetic medicine into Brazil’s
universal healthcare system was approved by the government
as the National Policy to Clinical Genetics Care (http://www.
in.gov.br/imprensa/visualiza/index.jsp?jornal = 1&pagina =
50&data = 21/01/2009). Under this law, public healthcare
systems and private insurance companies are requested to
reimburse a limited amount of genetic testing. However, the
implementation of this law requires regulation. Its final
approval/regulation will be welcomed, as there will be better
medical care for patients and their at-risk relatives.
In conclusion, genomic medicine should be predictive,
personalized, preventive, and participatory. It has been
implemented mostly in developed countries, and several
issues remain in applying genomic medicine to clinical
practice in emerging countries, such as Brazil. However, this
needs to be achieved quickly in order to patients take
advantage of this era of evidence-based molecular diag-
nosis. The effort is worthwhile; after all Whoever saves a life, it
is considered as if he saved an entire world (Mishnah Sanhedrin
455).I If the purpose of applying the accumulating data from
genomic medicine to clinical practice in emerging countries
is achieved, it will be another step in reaching the main goal
of medicine – to save lives.
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